# Progress Note 04 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Julius Caesar (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-AC001-SYN
- Date: 2026-09-15
- Fictional facility: St. Posthumous Health Center
- Fictional author: Lucius Fairbanks-Okonkwo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Four-week review of levetiracetam, blood pressure, and the rhythm monitor. **S**

## History of present illness

Julius Caesar returns four weeks after starting levetiracetam, atorvastatin, and aspirin. He has had no seizure, spell, or confused awakening. He was more irritable than usual in the first week, which has passed; he is not low in mood and has no thoughts of self-harm. His cold from last week has gone. He has no muscle aches, bruising, or bleeding. His home blood pressure readings over two weeks average 134/84 mmHg. The second rhythm monitor, removed yesterday, showed sinus rhythm throughout. The home sleep test showed no sleep apnea. He is not driving and has a riding companion at weekends. **S**

| Element | Detail |
|---|---|
| Seizures | None since levetiracetam was started |
| Side effects | Irritability in the first week, now gone |
| Home blood pressure | Average 134/84 mmHg over two weeks |
| Monitor and sleep test | No atrial fibrillation; no sleep apnea |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Well; cold resolved |
| Musculoskeletal | Negative | No muscle aches |
| Neurological | Negative | No spell, weakness, numbness, or speech change |
| Psychiatric | Negative | Irritability settled; mood steady |
| Hematologic | Negative | No bruising or bleeding |

5 systems reviewed. **S**

## Current medications

- Lisinopril 10 mg oral tablet, one tablet by mouth daily **S**
- Levetiracetam 500 mg oral tablet, one tablet by mouth twice daily **S**
- Atorvastatin 80 mg oral tablet, one tablet by mouth at bedtime **S**
- Aspirin 81 mg delayed-release tablet, one tablet by mouth daily **S**
- Amlodipine 5 mg oral tablet, one tablet by mouth daily **S**

## Allergies

- No known allergy **S**

## Objective

BP 136/84 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 98% on room air; weight 75.6 kg; BMI 22.8 kg/m². All vital signs are synthetic.

PHQ-9: 4; MoCA: 28. All results are synthetic.

## Change since baseline

- PHQ-9: 3 at baseline, 4 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well |
| Cardiovascular | Regular rhythm; blood pressure 136/84 mmHg |
| Neurological | No focal deficit; normal gait |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Focal epilepsy on levetiracetam** (G40.209). Seizure-free for four weeks; early irritability has settled. PHQ-9 4, item 9 scored 0. **S**
   - Continue levetiracetam 500 mg twice daily.
   - Seizure diary.
2. **Chronic left temporal cortical infarct** (I69.398). More than 40 days of monitoring without atrial fibrillation, so aspirin, not an anticoagulant, is right. No sleep apnea. MoCA 28 of 30: normal. **S**
   - Continue aspirin 81 mg and atorvastatin 80 mg.
3. **Hypertension** (I10). 136/84 mmHg in the office and 134/84 mmHg at home on lisinopril 10 mg: above target. **S**
   - Add amlodipine 5 mg daily; ankle swelling explained.
   - Continue the home log.
4. **Acute viral upper respiratory infection** (J06.9). Resolved without complications; no seizure during it. **S**
   - No further action.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Examination | Blood pressure (target below 130/80 mmHg) | Every visit | Completed today | 136/84 mmHg; home average 134/84 mmHg; amlodipine added |
| Self-management | Home blood pressure monitoring | Daily while treatment is adjusted | Completed today | Two weeks of stored readings reviewed |
| Imaging | Ambulatory rhythm monitoring for atrial fibrillation | At least 30 days within six months of the event | Completed today | More than 40 days in all; no atrial fibrillation |
| Examination | Sleep apnea evaluation | Consider after any stroke | Completed today | Home sleep test: apnea-hypopnea index 4 per hour; no sleep apnea |
| Survey | Depression screen (PHQ-9) | At the first visit after the event, then periodically | Completed today | 4; item 9 scored 0 |
| Survey | Cognitive screen (MoCA) | In the first year after a stroke | Completed today | 28 of 30 |
| Laboratory | Lipid panel after starting a statin | 4 to 12 weeks after starting | Due | At the ten-week visit |
| Medication safety | Statin tolerance | Every visit | Completed today | No muscle aches |
| Medication safety | Antithrombotic adherence and bleeding | Every visit | Completed today | Aspirin taken daily; no bruising or bleeding |
| Medication safety | Antiseizure medicine: seizures, adherence, and side effects | Every visit | Completed today | No seizure; irritability in the first week only; no missed doses |
| Examination | Fall risk | Every visit | Completed today | No falls |
| Examination | Weight and BMI | Every visit | Completed today | 75.6 kg; BMI 22.8 |
| Self-management | Tobacco, alcohol, physical activity, and diet | Every visit | Completed today | Diet changes kept up; walking daily; alcohol unchanged |
| Self-management | Seizure safety and driving | Every visit | Completed today | Not driving; riding only with a companion; seizure-free for four weeks |

## Goal progress

- Cause of the spells established and explained to him by the neurology visit. Outcome by 2026-08-18: Focal epilepsy with a structural vascular cause, from a chronic left temporal cortical infarct; syncope and transient ischemic attack judged unlikely. **S**
- No seizures on levetiracetam through the ten-week review. In progress; target 2026-10-27. **S**
- Office blood pressure below 130/80 mmHg. In progress; target 2026-10-27. **S**
- LDL cholesterol below 70 mg/dL on a high-intensity statin. In progress; target 2026-10-27. **S**
- No driving, swimming alone, or riding alone while the seizure-free period is counted, with a written seizure action plan for his staff. In progress; target 2026-10-27. **S**

## Medication changes

- Started: Amlodipine 5 mg oral tablet, one tablet by mouth daily **S**

## Guideline basis

- Practice guideline update summary: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new-onset epilepsy (2018), American Academy of Neurology and American Epilepsy Society (Neurology)
- 2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack (2021), American Heart Association and American Stroke Association (Stroke)
- 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025), American Heart Association and American College of Cardiology (Hypertension)
- CMID: Clinical Monitoring Intelligence Database, stroke and transient ischemic attack, hypertension, and hyperlipidemia monographs (2026), Aether Forge

## Follow-up

- Adult preventive visit in three weeks; ten-week chronic-care review with the lipid panel. **S**
- Next scheduled visit 2026-10-06: adult preventive visit. **S**
